Your browser doesn't support javascript.
loading
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot, Frédéric; Castanon, Eduardo; Baldini, Capucine; Hollebecque, Antoine; Carmona, Alberto; Postel-Vinay, Sophie; Angevin, Eric; Armand, Jean-Pierre; Ribrag, Vincent; Aspeslagh, Sandrine; Varga, Andrea; Bahleda, Rastislav; Menis, Jessica; Gazzah, Anas; Michot, Jean-Marie; Marabelle, Aurélien; Soria, Jean-Charles; Massard, Christophe.
Afiliação
  • Bigot F; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Castanon E; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Baldini C; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Hollebecque A; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Carmona A; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Calle Marqués de los Vélez s/n, Murcia, Spain.
  • Postel-Vinay S; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Angevin E; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Armand JP; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Ribrag V; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Aspeslagh S; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Varga A; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Bahleda R; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Menis J; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Gazzah A; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Michot JM; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Marabelle A; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Soria JC; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Massard C; University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France. Electronic address: massard@gustaveroussy.fr.
Eur J Cancer ; 84: 212-218, 2017 10.
Article em En | MEDLINE | ID: mdl-28826074
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos / Indicadores Básicos de Saúde / Ensaios Clínicos Fase I como Assunto / Seleção de Pacientes / Imunoterapia / Neoplasias / Neutrófilos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos / Indicadores Básicos de Saúde / Ensaios Clínicos Fase I como Assunto / Seleção de Pacientes / Imunoterapia / Neoplasias / Neutrófilos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França